TransMedics revenue up 41% to USD 203M in Q3 2026
TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.
How this was made

The 30-second read
Why it matters
Revenue beat and record case volume suggest strong demand for the company's logistics platform, supporting a potential price rally. Margin compression and lower net income warrant monitoring.
Market read
Earnings release provides fresh data for traders; the 41% revenue jump is material and may drive short‑term price movement.
What to watch
Future revenue from ENHANCE Heart Part B and DENOVO Lung not yet realized; growth may be delayed.
Background
TransMedics Group, Inc. (NASDAQ: TMED) provides organ preservation and transport solutions. The Q3 2026 results were released on Nov 7, 2026.
Market effects
Positive signal for organ‑transplant logistics and medical device sector, may lift peers.
U.S. biotech/medical device market may see modest buying pressure.
Limited to healthcare investors; no broad market impact.
Counterpoint
Net income decline and higher operating expenses could signal margin pressure; caution on upside.
Key entities
- CompanyTransMedics Group, Inc.
Medical device company reporting Q3 2026 results.



